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We evaluated the association of the sex hormone pattern and the serum level of the main adipokines to metabolic syndrome
(MS) and its components in 199 pharmacologically untreated subjects. Men and women included in the age-class subgroups
were matched for body mass index, waist circumference, blood pressure, heart rate, fasting plasma glucose, and plasma lipids.
Men without MS had significantly lower leptin/adiponectin ratio than men with MS. Women without MS had lower leptin and
leptin/adiponectin ratio than women with MS but had significantly higher adiponectin, estrone, and dehydroepiandrosterone
levels. In men, the leptin/adiponectin ratio is the main factor associated to MS diagnosis (OR: 3.36, 95% CI 1.40–8.08), while
in women adiponectin alone appears to be a protective factor (OR: 0.87, 95% CI 0.79–0.95). In conclusion, in a sample of
pharmacologically untreated subjects, leptin/adiponectin ratio seems to be the factor more strongly associated to MS and its
components.
1. Introduction
The metabolic syndrome (MS) is a highly prevalent complex
pathophysiological condition associated to increased cardio-
vascular disease risk. Interestingly, the risk profile related
to the metabolic syndrome appears to be diﬀerent in men
and women [1]. This could be at least partly related to
the diﬀerent hormonal pattern and to the diﬀerent adipose
tissue metabolism [2]. In fact, women generally have a larger
proportion of body mass as fat and are more likely to
accumulate fat subcutaneously and on their lower extrem-
ities, whereas men are more likely to accumulate fat in the
abdominal region [3]. In addition, women have higher rates
of nonesterified fatty acids (NEFAs) reuptake by the adipose
tissue. However, they also have greater rates of fat oxidation
during prolonged exercise: oestrogens appear to underlie
many of these diﬀerences [4]. Fat and fertility are linked
through leptin in humans, and in women, reduced fertility
has been indeed associated with reduced leptin plasma levels
[5]. On the other side, leptin secretagogues have similar eﬃ-
cacy in subjects with diﬀerent body weight, yet significantly
higher in women than in men [6]. Moreover, physiologi-
cal conditions (menopause, and aging) that influence the
pattern of sex hormones are also associated to changes in
the synthesis and secretion of adipokines, which contribute
to the development of MS, target organ damage, and other
chronic diseases [7]. Adipokines have actually been related
to carotid atherosclerosis [8] and coronary calcification [9].
2 International Journal of Endocrinology
The interrelationship between sex hormones and adipokine
levels has been observed in diﬀerent studies. Adiponectin
was found to be lower in men, in comparison to women,
[10] despite an inverse relationship between estradiol and
adiponectin, [11] indicating that in addition to estradiol,
other gender-dependent factors may be of relevance. The
relationship between testosterone and adiponectin is less
clear. While in rodents, testosterone injection decreases
adiponectin levels, [12] in healthy adult-elderly humans,
[13] and in women aﬀected by polycystic ovary syndrome,
[14] serum adiponectin and testosterone are directly cor-
related. However, when compared with eugonadal subjects,
hypogonadal men have greater adiponectin levels, which
are reduced by testosterone replacement therapy [15]. On
the other hand, in males, negative correlations between
testosterone and leptin have been clearly shown in diﬀerent
cross-sectional studies, [16, 17] including one from our
group [18]. In addition, testosterone therapy reduces serum
leptin concentrations in subjects with low testosterone levels
[19]. The explanation for such relationship is the presence
of functional leptin receptors in reproductive tissues and,
reciprocally, of steroid hormone receptors on adipocytes.
Although the exact role of leptin is not fully understood,
this adipokine is well known to be involved in normal sexual
maturation and reproduction [20].
On this basis, the aim of our study was to evaluate the
association of the sex hormone pattern and the serum level
of the main adipokines toMS and its components in a cohort
of pharmacologically untreated subjects.
2. Materials and Methods
2.1. The Brisighella Heart Study. The Brisighella Heart Study
is a prospective, population-based longitudinal epidemiolog-
ical cohort involving 2939 randomly selected subjects, aged
14 to 84 years, free of cardiovascular disease at enrolment,
resident in the Northern Italian rural town of Brisighella.
The study was promoted in 1972 by Professor G. Descovich
[21]. Subjects were clinically evaluated at baseline and every
4 years following enrolment when extensive clinical and
laboratory data were obtained in addition to the assessment
of morbidity and mortality. In 1986, the study became part
of the WHO European Risk Factors Coordinated Analysis,
and in 1990, it became part of the Risk Factors and Life
Expectancy Project [22]. Throughout the duration of the
entire study, all-cause mortality and morbidity, as well as
the incidence of the main cardiovascular risk factors, were
recorded. Every three months, the study design included an
update of the database with regard to fatal and nonfatal
new events and every four years, a complete medical
checkup comprised a nutritional habits record and fasting
blood sample was performed. From 1986 to 1988, several
programs started to check eﬃcacy, cost, and reliability of
primary and secondary cardiovascular prevention, including
school children and general population nutritional educa-
tion programs and general practitioner training concerning
therapeutic guidelines [21]. Physical activity and nutritional
habits have been recorded throughout the study and encoded
as previously reported [22]. The study was carried out in
agreement with the Declaration of Helsinki. It was approved
by the Ethical Committee, and all subjects gave their written
consent to be involved in the study.
2.2. Subject Selection. For this study, from the database of the
historical cohort of the Brisighella Heart Study, we selected
adult male and women subjects classified as healthy and free
of antihypertensive, lipid-lowering, or antidiabetic drugs,
representative of their age, and cross-matched by age, body
mass index (BMI), systolic blood pressure (SBP), diastolic
blood pressure (DBP), pulse pressure (PP), heart rate (HR),
respiratory rate (RR), total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), triglycerides (TG), and
fasting plasma glucose (FPG). HR and RR were included as
selection criteria as indirect markers of sympathetic activity
that is related to MS and, more generically, overweight
[23]. Plasma lipids were included as selection criteria to
exclude a priori people aﬀected by metabolic diseases and
because we did not select patients on the basis of nutritional
habits: since TG (and consequently HDL and LDL) could be
strongly influenced by dietary factors, [24] we preferred to
standardize patients on the basis of their lipid values as an
indirect markers of correct dietary habits.
The final sample included 199 subjects (M:89; F:110),
aged 62.5 ± 12.4 years. The main characteristics of the
selected subjects are reported in Table 1.
2.3. Laboratory Methods. All the assays have been carried out
on 12-hour fasting sampled blood. Routine hematochemical
analyses have been carried out using standardized methods.
Plasma leptin, adiponectin, and testosterone concentrations
were measured using enzyme-linked immunoSorbent assay
(ELISA) kits from R&D Systems (Minneapolis, Minn, USA)
[25]. The lowest limits of sensitivity were 7.8 pg/mL for
leptin, 0.246 ng/mL for adiponectin, and 0.030 ng/mL for
testosterone. Ghrelin was measured using the human ghrelin
(total) ELISA kit fromMillipore (St. Charles, Mo, USA) [26].
The lowest level of total ghrelin that can be detected by this
assay is 30 pg/mL. Plasma estrone and dehydroepiandros-
terone sulphate (DHEAS) levels were detected by ELISA kits
from BioVendor (Heidelberg, Germany). The lowest limits of
sensitivity were 10.0 pg/mL for estrone and 0.005 µg/mL for
DHEAS.
2.4. Statistical Analysis. Patients were classified as aﬀected
or not by MS on the basis of the NCEP ATPIII guidelines
[27]. A full descriptive analysis of the available parameters
was carried out, and continuous variables were tested
for normality according to the Kolmogorov-Smirnov test.
Results were reported as mean ± standard deviation for
normally distributed parameters and as median ± 95%
confidence intervals for not-normally distributed variables.
Not-normally distributed variables were log-transformed in
order to carry on advanced statistics. The association of sex
hormones, adipokines, and MS and its components has been
evaluated by the application of a logistic regression model
and the age-adjusted odds ratio (OR) with 95% confidence
intervals (CI) have been calculated. The model included
all variables not directly related to that considered in the
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Table 1: Main clinical and laboratory characteristics of the studied population.
Variable
Men (N . 89) Women (N . 110)
Mean SD Mean SD
Age (years) 63.55 12.91 61.68 11.88
BMI (kg/m2) 27.08 3.37 28.04 4.94
SBP (mmHg) 140.06 18.39 142.82 20.46
DBP (mmHg) 81.84 9.83 83.55 10.70
Pulse pressure (mmHg) 58.22 17.69 59.26 14.40
Heart rate (ppm) 71.12 9.85 72.70 8.84
Respiratory rate (rpm) 20.02 3.18 21.59 6.25
TC (mg/dL) 213.91 30.97 223.80 31.53
TG (mg/dL) 138.45 66.14 128.60 51.20
HDL-C∗ (mg/dL) 47.43 10.22 52.40 13.84
LDL-C (mg/dL) 138.78 30.64 147.67 31.52
Non-HDL-C (mg/dL) 166.47 32.43 171.39 35.91
FPG (mg/dL) 101.45 25.34 99.19 22.75
∗
Men versus women, P < 0.05.
definition of MS. A threshold “P” level < 0.05 was chosen
as significant for all the tests. All analyses were carried out
with the help of SPSS 13 version for Windows.
3. Results
MS was present in 27 (31.4%) men and 45 (43.3%) women
(Pearson Chi-Square = 2,82. P = 0.093). The percent
distribution of the individual MS components has been sum-
marized in Figure 1. Men tended to have TG above the MS
diagnostic cutoﬀ whereas women to have waist circumfer-
ence and HDL-C above and below the diagnostic cutoﬀ,
respectively.
Adipokine and sex hormone levels are reported by gender
and MS diagnosis in Table 2. Among subjects without
MS, men had a leptin/adiponectin ratio significantly lower
than women; among subjects with MS, men had signif-
icantly lower leptin, adiponectin, and leptin/adiponectin
ratio than women, who showed significantly higher estrone,
and DHEAS.
Comparing subjects with and without MS within gen-
ders, men without MS had significantly lower leptin/ad-
iponectin ratio than men with MS. On the other side,
women without MS had lower leptin and leptin/adiponectin
ratio than women with MS but had significantly higher
adiponectin, estrone and DHEAS levels.
In men, the leptin/adiponectin ratio is the main factor
associated to MS diagnosis (OR: 3.36, 95% CI 1.40–8.08),
while in women, adiponectin alone appears to be a protective
factor against this diagnosis (OR: 0.87, 95% CI 0.79–0.95).
The main factors associated to individual MS criteria are
reported in Table 3.
4. Discussion
Whereas there are contrasting data about the association of
leptin/adiponectin ratio and vascular damage, [8, 28] it is
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Figure 1: Percentage distribution of metabolic syndrome compo-
nents between genders. ∗P < 0.05 between men and women.
largely accepted that this ratio is strongly associated with
insulin resistance, which represents the major feature of
the MS [29]. In our study, carried out in a representative
sample of pharmacologically untreated adult-elderly subjects
involved in the Brisighella Heart Study, we observed that
in men, the leptin/adiponectin ratio is the main factor
associated to MS diagnosis, while in women, adiponectin
alone appears to be a protective factor. Considering the
relatively old age of the women participating in our study,
this result is in line with what just reported by Milewicz et al.
[30].
When the MS components are considered individually,
we observed that in men, the leptin/adiponectin ratio acted
as the factor more strongly associated to higher blood
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Table 2: Adipokine and sex hormone levels by gender and metabolic syndrome diagnosis.
Variable
No Metabolic syndrome Metabolic syndrome
Men (N . 61) Women (N . 28) Men (N . 63) Women (N . 47)
Mean SD Mean SD Mean SD Mean SD
Adiponectin (pg/mL) 10.19 4.78 15.57◦ 6.86 8.39∗ 4.90 11.32 5.06
Leptin (pg/mL) 4.67 4.05 13.23◦ 10.47 6.31∗ 3.72 19.45 13.34
Leptin/adiponectin 0.54∗◦ 0.48 1.11◦ 1.14 0.97∗ 0.76 2.17 1.75
Ghrelin (pg/mL) 758.33 202.98 730.35 230.63 729.32 152.72 724.65 188.84
Testosterone (ng/mL) 7.00 5.28 2.04 1.57 6.46 2.72 1.76 1.32
Estrone (pg/mL) 153.07 139.52 153.21◦ 142.20 234.79∗ 250.39 106.32 58.75
DHEAS (µg/mL) 1.10 0.59 0.90◦ 0.53 1.08∗ 0.62 0.69 0.43
Testosterone/estrone 0.06 0.04 0.01 0.02 0.05 0.03 0.01 0.01
∗P < 0.05 between men and women.
◦P < 0.05 versus subjects of the same sex without MS.
Table 3: Factors associated to the single metabolic syndrome components in men and women.
MS component
Men Women
Variable OR 95% CI Variable OR 95% CI
Waist circumference Uric acid 2.21 1.3–3.6 L/A ratio 4.43 1.87–10.47
Blood pressure L/A ratio 4.73 1.01–14.43
Testosterone 2.18 1.09–4.36
L/A ratio 2.19 1.01–6.02
Fasting plasma glucose Estrone 1.01 1.01–1.05 Adiponectin 0.86 0.76–0.97
Triglycerides L/A ratio 2.87 1.23–6.67 Uric acid 1.85 1.18–2.91
HDL-cholesterol L/A ratio 2.84 1.22–6.61 Uric acid 1.93 1.23–3.01
L/A: Leptin/Adiponectin Ratio.
pressure and triglycerides and lower HDL-C level, while in
women, this was best associated to higher blood pressure and
waist circumference. Testosterone was strongly associated to
high blood pressure in women, while estrone was mildly
associated to high fasting plasma glucose in men.
In fact, testosterone favors visceral fat accumulation, and
inflammatory pattern in women, thus possibly enhancing
an intrinsic blood pressure increasing trend [31] although
some protective eﬀects have been recently postulated by
other authors [32]. Should the latter be confirmed by further
studies, the correlation between T levels and blood pressure
we observed in women might be even interpreted as a com-
pensatory mechanism.
In men, estrone comes mostly from androgen metab-
olism within the adipose tissue, and therefore, its parallel
increase with fasting plasma glucose might reflect the relative
increase in fat accumulation and insulin resistance somehow
expected from early steroid physiology studies supported by
more recent clinical evidence [33, 34]. Adiponectin seems
to be a protective factor against high FPG in women. In-
terestingly, uric acid, included in the original Reaven’s MS
definition, [35] appeared to be strongly associated to high
waist circumference in men and to the typical atherogenic
dyslipidemia in women.
Overall, these data support the observations showing
that a large part of cardiovascular risk factors are related to
adipose tissue metabolism but with diﬀerent features in men
and women [36]. These observations are actually relevant
when planning preventive interventions in the setting of
general population, where they need to be adapted to each
gender [37].
Our study has some relevant limitations. The first is the
relatively small size of the study cohort. In any case, the
subjects have been selected as representative for their age
classes in the general population, and they are pharmaco-
logically untreated (in order to avoid interference on the
hormonal and adipokine pattern).Moreover, we have limited
our research to some sex hormones and adipokines, while
we are aware that several other related parameters could be
investigated. Besides, at the best of our knowledge, in the
present study, we investigated the more widely accepted and
cited parameters. Therefore, the lack of diﬀerences among
groups in ghrelin concentration, previously reported by
other authors, [38] could be related to our patients selection,
with similar baseline HR and RR: in fact, very recent evidence
show that ghrelin modulates the sympathetic activity [39]
and our observation is probably an indirect confirmation of
these data.
In conclusion, in a sample of pharmacologically untreat-
ed adult-elderly subjects, leptin/adiponectin ratio seems to
be the factor more strongly associated with MS (especially
in men) and its components even if diﬀerently in men and
women.
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